Rezatapopt PYNNACLE trial infographic showing 48% response rate in platinum-resistant ovarian cancer

Rezatapopt, PMV Pharmaceuticals’ experimental pill that repairs a specific broken form of the p53 tumour-suppressor protein, shrank tumours in 48% of 65 women with platinum-resistant or refractory ovarian cancer in the pivotal Phase 2 PYNNACLE trial, according to updated results released on November 20, 2026 at the ENA 2026 symposium in Barcelona. Responses lasted a median of 10.4 months, and the company plans to file for accelerated FDA approval in the first quarter of 2027.

Key takeaways on rezatapopt

  • Rezatapopt is an oral, once-daily small molecule designed for tumours carrying the TP53 Y220C mutation.
  • In the primary ovarian cancer analysis, 31 of 65 patients responded (one complete, 30 partial), and 83% had disease control.
  • Across all tumour types, the response rate was 36% in 168 evaluable patients, with responses in ovarian, endometrial, lung, breast and several rarer cancers.
  • Most treatment-related side effects were grade 1 or 2; nausea, vomiting and fatigue were among the most frequent.
  • The trial is single-arm, so it cannot show how rezatapopt compares with existing therapy. An NDA for accelerated approval is planned for Q1 2027.

Why p53 has been called undruggable

TP53 is the most commonly mutated gene in human cancer. Its protein, p53, normally halts cell division when DNA is damaged and can trigger a damaged cell to self-destruct. When the gene is mutated, that brake fails. For decades, drug developers struggled because most p53 mutations destroy function rather than create a new target to block, and fixing a broken protein is far harder than switching off an overactive one.

Rezatapopt takes a narrow, structural approach. The Y220C mutation creates a small pocket that destabilises the p53 protein. The drug is designed to sit in that pocket, hold the protein in its normal shape and restore its tumour-suppressing activity. That means it only works for one mutation, so patients need tumour genetic testing to qualify.

The PYNNACLE numbers in one table

GroupPatientsResponse rateNotes
Platinum-resistant/refractory ovarian (primary analysis)6548% confirmedMedian response duration 10.4 months; disease control 83%
All ovarian cancer10145%Includes four unconfirmed partial responses
Endometrial cancer1145%Small cohort
Lung cancer1921%Confirmed responses
Breast cancer1817%Confirmed responses
Other solid tumours1921%Includes head and neck, colorectal, gallbladder, ampullary
All tumour types16836%Median response duration 8.1 months; median time to response 1.3 months
Data cutoff September 4, 2026, investigator-assessed per RECIST v1.1, as reported by PMV Pharmaceuticals.

The ovarian population was heavily pretreated. Patients had a median of four prior lines of therapy, 93% had high-grade serous disease and 97% had platinum-resistant or refractory cancer. In that setting, standard non-platinum chemotherapy has historically produced response rates well below the levels seen here, which is why the 48% figure is drawing attention. Still, cross-trial comparisons are risky, and the absence of a control arm is the study’s main limitation.

A blood signal that the drug hits its target

PMV also tracked circulating tumour DNA. Among 50 patients with samples, 90% saw the amount of TP53 Y220C DNA in their blood fall by at least half within three to six weeks of starting treatment. That fits the idea that the drug is acting on the intended mutation. Whether an early ctDNA drop reliably predicts a lasting response has not yet been shown.

Safety and dosing in the trial

Patients took 2,000 mg by mouth once daily. Treatment-related adverse events were mostly grade 1 or 2, and events seen in more than 15% of patients included nausea, vomiting and fatigue. The safety population included 180 patients. Full tolerability details, including discontinuation rates and serious events, will matter to regulators, and they are not yet fully public. This is trial data, not prescribing guidance.

Market context

Acumen Research and Consulting estimates the ovarian cancer treatment drugs market was worth US$3.3 billion in 2022 and will reach US$6.4 billion by 2032, growing at a 6.8% compound annual rate. Acumen found PARP inhibitors held the largest share by drug class, targeted therapy led by treatment type, North America dominated and Asia-Pacific is growing fastest. A mutation-matched oral option for platinum-resistant disease would add a new targeted segment to a market where many patients eventually run out of PARP and platinum options.

What to watch before an FDA decision

Three questions will shape rezatapopt’s path. First, whether the FDA accepts single-arm data for accelerated approval, which normally requires a confirmatory randomised trial to be underway. Second, how a companion diagnostic will identify Y220C patients in routine practice. Third, whether responses hold up with longer follow-up. ENA 2026 has been a busy meeting for precision oncology, with results such as daraxonrasib in first-line pancreatic cancer and the ERAS-0015 pancreatic cancer pill also presented. Follow more readouts in our clinical trials section.

FAQ

What is rezatapopt used for?

It is an investigational drug for advanced solid tumours with the TP53 Y220C mutation, studied most closely in platinum-resistant ovarian cancer. It is not yet approved anywhere.

How effective is rezatapopt in ovarian cancer?

In the PYNNACLE primary analysis, 48% of 65 patients had confirmed tumour shrinkage, with a median response duration of 10.4 months.

When could rezatapopt be approved?

PMV Pharmaceuticals plans to submit an NDA seeking accelerated approval in Q1 2027. An FDA decision would follow review, so approval in 2027 is possible but not assured.

How do I know if my tumour has the TP53 Y220C mutation?

Only tumour genomic testing, such as next-generation sequencing of tissue or blood, can identify it. Ask your oncologist whether such testing is appropriate.

Sources: PMV Pharmaceuticals announcement of updated PYNNACLE Phase 2 data, November 20, 2026 (ENA 2026); ClinicalTrials.gov NCT04585750. Market data: Acumen Research and Consulting. Not medical or investment advice. Last updated November 21, 2026.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

Leave a Reply

Your email address will not be published. Required fields are marked *